The data safety data suggests that the Leronlimab

Quote:

---

The data safety data suggests that the Leronlimab group will have better outcomes than the placebo group as less patients progressed to severe conditions as measured by SAE.

Read More: https://investorshangout.com/post/newpost/605...z6SsNWBCjM

---

One point I would like to add: SAE can happen at anytime. It's entirely possible, and quite likely, that some of the SAE in the treatment arm occurred early on, before Leronlimab had a chance to work.

Why is this important? Because our primary endpoint is the improvement of symptoms. This creates a situation where it is entirely likely that the p value power of the primary endpoint will be STRONGER than the SAE alone.